Cognitive Assessment and Training in Healthcare Market Size, Share & Industry Analysis, By Assessment Type (Pen and Paper, Biometrics, and Hosted), By Application (Screening and Diagnostics, Clinical Trials, Brain Training, and Others), and Regional Forecast, 2024-2032

The global cognitive assessment and training in healthcare market size was valued at USD 4.46 billion in 2023. The market is projected to grow from USD 5.12 billion in 2024 to USD 18.29 billion by 2032, exhibiting a CAGR of 17.2% during the forecast period.

Cognitive assessment and training in healthcare tools are used to assess the mental functioning of the patient. These tools can help to screen and train individuals with neurological disorders such as Alzheimer's, dementia, Mild Cognitive Impairment (MCI), and depression. These tools also help healthcare providers to understand the mental health of patients. If a significant decline in mental functioning is observed, further referral to a neurologist may be necessary. The increasing prevalence of such neurological disorders has been fueling the demand for cognitive assessment and training in healthcare. For instance, as per a research article published by Frontiers Media S.A. in 2022, the global prevalence of MCI was around 15-20%.

Moreover, the incorporation of cognitive assessment in clinical trials is helpful in understanding the effect of treatment on the human brain. Therefore, the boost in the number of clinical trials for the development of effective vaccines and drugs for the virus during the COVID-19 pandemic in 2020 fueled the demand for cognitive assessment, thereby positively impacting the market growth.

Cognitive Assessment and Training in Healthcare Market Trends

Increasing Trend of Virtual Clinical Trials to Augment Demand for Cognitive Assessment and Training in Healthcare

In clinical trials for effective treatment for specific conditions, cognitive and technical assessments are incorporated to study the effect of drug candidates on patients’ brains by assessing their cognitive functioning. These tests help in understanding whether the drug is helping in brain development or not. During the sudden outbreak of COVID-19, many research studies were temporarily put on hold as the researchers were not able to visit research sites due to lockdown restrictions. This led to the emergence of decentralized clinical trials, which are conducted using virtual patient monitoring, wearable medical devices, remote SDV, and other advanced technologies.

In decentralized clinical trials, patients can participate remotely, and they are monitored through digital tools. This factor has fueled the participation of patients in these trials, as the patients can join from the convenience of their homes. Decentralized clinical trials allow patients to participate in research studies irrespective of their location.

• For instance, as per an article published by mdgroup in 2023, it had been observed in many studies that around 70% of the patients were only present for around 2 hours at the research site for monitoring. Whereas in decentralized trials, the patients can be monitored for more hours as required by the researchers.

The increasing number of decentralized clinical trials has been fueling the adoption of digital cognitive assessments and training in healthcare. In decentralized clinical trials with digital cognitive assessment features, registered patients do not have to go to the research center, and complete their cognitive assessments online. Researchers can easily review the assessments without actually meeting the patients in person. The incorporation of digital cognitive assessment and training in healthcare has proved to be quite helpful and convenient for virtual clinical trials. This has increased the awareness of digital cognitive assessments among patients and is responsible for the market’s growth.

Cognitive Assessment and Training in Healthcare Market Growth Factors

Increasing Number of Clinical Trials for Neurological Diseases to Fuel Demand for Cognitive Assessment

It is essential to study cognitive changes in preclinical and clinical studies for neurological diseases, such as Alzheimer’s. Therefore, the increasing number of clinical trials for these diseases has been one of the significant factors fueling the demand for cognitive assessment. For instance, as per data published by the National Center for Biotechnology Information (NCBI), till January 2022, around 143 drug candidates were being studied in 172 clinical trials for Alzheimer’s disease. A total of 50,575 patients were required to conduct the clinical studies. These patients also need to be regularly monitored for cognitive changes.

Furthermore, the increasing awareness and prevalence of neurological diseases have been fueling the demand for these products and services.

• For instance, as per the data published by John Wiley & Sons, Inc. Journal, as of January 2024, around 164 clinical trials are being conducted globally, assessing 124 drug candidates for Alzheimer’s disease. However, the number of clinical trials being conducted in 2021 was around 152, assessing around 126 drugs.

This increasing prevalence of neurological diseases and the growing number of clinical trials for these diseases have been fueling market growth.

Increasing Prevalence of Neurological Disorders have been Fueling the Demand for Effective Cognitive Assessment Tools

The increasing prevalence of neurological disorders such as Alzheimer's, dementia, mild cognitive impairment (MCI), and depression along with the rising awareness regarding the cognitive assessment tools has been fueling the demand for cognitive assessment and training in healthcare tools.

• For instance, as per data published by the Alzheimer's Association in 2023, around 6.7 million individuals aged 65 and older in the U.S. had Alzheimer’s disease.


• Similarly, as per a research study published by BioMed Central Ltd. in May 2023, around 4.05% suffered from anxiety disorder worldwide.

Therefore, the increasing prevalence of disorders such as mild cognitive impairment (MCI) and dementia has been driving the adoption of cognitive assessment. Additionally, increasing awareness about cognitive assessment for learning disabilities, cognitive assessment in occupational therapy, and screening for neurological disorders, has further contributed to cognitive assessment and training in healthcare market growth.

RESTRAINING FACTORS

Limitations Associated with the Cognitive Assessment and its High Cost to Limit Market Growth

The growing burden of neurological disorders and the increasing awareness regarding cognitive assessment and training in healthcare have increased the adoption of these assessment tools. However, certain limitations associated with cognitive assessments have been restricting their global adoption. Montreal cognitive assessment (MoCA) is considered a gold standard in neuropsychological tests, but its efficacy in varied populations is not well defined.

• For instance, as per a research study published by the Albert Einstein College of Medicine in January 2024, researchers observed that the cut-off scores used in the Montreal Cognitive Assessment (MoCA) for the study’s patients were very high, which can result in the wrong identification of cognitive impairment.

Furthermore, these tests can be very costly depending upon the type of test, duration of the complete test, and complexity in giving the results.

• For instance, in France, the cost of a basic cognitive assessment test package (including multiple tests) can be around USD 600.0 – 800.0 and can go as high as USD 1,000.0 - 1,200.0. It can go much higher depending on the complexity and the patient’s requirements.

Due to such factors, patients avoid going for such screening tests and opt directly for neurological disease diagnosis, thereby limiting market growth.

Cognitive Assessment and Training in Healthcare Market  Segmentation Analysis

By Assessment Type Analysis

Pen and Paper Segment dominated due to Adoption of AI in Cognitive Assessments

Based on assessment type, the market is segregated into pen and paper, biometrics, and hosted.

The pen and paper segment dominated the cognitive assessment and training in the healthcare market in 2023. The segment’s dominance in the global market is attributed to the cost-effectiveness of these tools and the emergence of AI-based pen and paper assessments.

• For instance, as per the data published by SCIENTIFIC AMERICAN in May 2024, Linus Health combined an established pen and paper test based on a simple drawing test with artificial intelligence to make it easier to administer.

The biometrics segment is expected to grow at the fastest CAGR during the forecast period. The growth of the segment during the forecast period is attributed to the increasing prevalence of neurological disorders and the efficiency of these tools.

• For instance, as per the data provided by the World Health Organization (WHO) in March 2023, around 55.0 million people globally were diagnosed with dementia. Moreover, as per the same source, around 10.0 million new cases of dementia are diagnosed globally every year.

By Application Analysis

Clinical Trials Segment Led owing to Increasing Adoption of Cognitive Assessment

Based on application, the market is segmented into screening and diagnostics, clinical trials, brain training, and others.

The clinical trials segment dominated the market in 2023 and is expected to grow at a significant CAGR during the forecast period. The growth of the segment is attributed to market players’ increasing focus on new product launches to increase the efficiency of cognitive assessment.

For instance, in October 2023, Cambridge Cognition Ltd launched Aqua, an automated quality assurance solution for central nervous system (CNS) clinical trials. AQUA utilizes Winterlight's speech and language platform and employs audio recordings from patient consultations to detect errors in the administration and scoring of cognitive assessments.

The screening and diagnostics segment is expected to grow at the fastest CAGR during the forecast period. The growing penetration of digital cognitive assessment tests and the rising prevalence of neurological disorders is responsible for the segment’s growth during the forecast period. Moreover, growing partnerships among key industry players for providing digital cognitive screening are also responsible for the segment’s growth.

• For instance, in December 2022, Neurotrack Technologies, Inc. announced a partnership with insurance provider Nationwide to offer digital cognitive screening for its CareMatters applicants, who required an alternative method for cognition assessment to the traditional telephone interview.

REGIONAL INSIGHTS

By geography, the market is studied across Europe, North America, Asia Pacific, and the rest of the world.

The North America region accounted for the largest cognitive assessment and training in healthcare market share by accounting for a revenue of USD 2.43 billion in 2023. The growth of the market in the region is attributed to the increasing focus of market players on new product launches.

• For instance, in November 2021, Cognetivity Neurosciences announced the U.S. Food and Drug Administration (FDA) approval of its CognICA (Integrated Cognitive Assessment) tool in the U.S.

The market in Europe is expected to record the fastest growth rate during the forecast period. This growth of the segment is attributed to the strong presence of market players such as Cambridge Cognition Ltd. and CogniFit Inc., in the region. Furthermore, the growing burden of neurological disorders and increasing demand for effective on-time screening and diagnosis have been fueling market growth in the region.

On the other hand, the market in the Asia Pacific is expected to grow at a substantial growth rate during the forecast period. The growth of the market in the region is due to the increasing focus of market players on expanding their presence and the increasing awareness regarding cognitive assessment tools.

• In November 2022, Cambridge Cognition Ltd announced its strategic partnership with Luca Healthcare Limited, one of the major players involved in providing digital screening, treatment, and management tools in China.

The rest of the world region, which consists of Latin America and the Middle East & Africa regions, is also expected to demonstrate steady growth during the forecast period due to the rising awareness about cognitive assessment and training in healthcare tools.

KEY INDUSTRY PLAYERS

Increasing Focus of Leading Players on Partnerships for Market Expansion is Responsible for Their Dominance

Cambridge Cognition Ltd, Pearson, Cogstate Ltd, PAR, Inc., and CogniFit Inc are some of the most prominent players in the market. This prominence is due to their strong emphasis on expanding their services globally through acquisitions and partnerships with other players.

• In March 2023, Pearson announced the acquisition of Personnel Decisions Research Institutes, LLC. This acquisition expanded the company’s product portfolio in cognition assessment and training in the healthcare market.

Furthermore, market players have also increased their focus on partnerships with other companies to expand their product offerings in the market.

• For instance, in April 2023, CogniFit Inc announced its partnership with Muhdo Health to launch a Cognitive Brain Age test within the Muhdo app.

Other leading companies, such as Clario, Cognetivity Neurosciences, and Signant Health, have increased their focus on the adoption of advanced technologies to enhance their product offerings. Moreover, market players have also been focusing on partnerships and mergers to expand their presence globally.

List of Top Cognitive Assessment and Training in Healthcare Companies:

• CogniFit Inc (U.S.)


• CNS Vital Signs, LLC (U.S.)


• Signant Health (U.S.)


• Posit Science (U.S.)


• Clario (U.S.)


• Linus Health (U.S.)


• PAR, Inc. (U.S.)


• KERNEL (U.S.)


• Neurotrack Technologies, Inc. (U.S.)


• Pearson (U.K.)


• Cogstate Ltd. (Australia)


• Cambridge Cognition Ltd (U.K.)


• Cognetivity Neurosciences (U.K.)


• Koninklijke Philips N.V. (Netherlands)


• Winterlight Labs (Canada)


• Aural Analytics (U.S.)

KEY INDUSTRY DEVELOPMENTS:

• April 2024 - CogniFit Inc entered into a partnership with Factorial. As a result of this partnership CogniFit Inc integrated its cognitive assessment and training tools into Factorial’s platform to support the overall well-being and productivity of employees and the organization.


• March 2024 - Linus Health announced the acquisition of Aural Analytics. This acquisition expanded the company’s cognitive assessment product portfolio.


• January 2024 - CogniFit Inc signed a partnership agreement with AON to mark a significant step toward prioritizing mental well-being in the corporate landscape.


• March 2023 - Clario announced its partnership with technology startup ArtiQ to increase chances in respiratory clinical trials requiring spirometry data.


• November 2022 – Clario announced the release of new data, confirming its leadership in providing remote data collection technologies that enable decentralized and hybrid clinical trials.

REPORT COVERAGE

The cognitive assessment and training in healthcare market report provides a detailed competitive landscape. It also includes key insights, such as top industry developments covering partnerships, mergers, and acquisitions. Additionally, it focuses on key points, such as new solution launches in the market. Furthermore, the report covers regional analysis of different segments, profiles of key market players, market trends, and the impact of COVID-19 on the market. The report consists of quantitative and qualitative insights that have contributed to the market's growth.

Report Scope & Segmentation

ATTRIBUTE	DETAILS
Study Period	2019-2032
Base Year	2023
Estimated Year	2024
Forecast Period	2024-2032
Historical Period	2019-2022
Growth Rate	CAGR of 17.2%  from 2024 to 2032
Unit	Value (USD Billion)
Segmentation	By Assessment Type Pen and Paper Biometrics Hosted
By Application Screening and Diagnostics Clinical Trials Brain Training Others
By Region North America (By Assessment Type, Application, and Country) U.S. Canada Europe (By Assessment Type, Application, and Country/Sub-region) U.K. Germany France Spain Italy Scandinavia Rest of Europe Asia Pacific (By Assessment Type, Application, and Country/Sub-region) China India Japan Australia Southeast Asia Rest of Asia Pacific Rest of the World  (By Assessment Type, Application)